Efficacy Biomarkers of DAOIB for Dementia

Launched by CHANG GUNG MEMORIAL HOSPITAL · Oct 13, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Efficacy Biomarkers of DAOIB for Dementia," is studying the potential benefits of a treatment called DAOIB for patients with mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD). Over 24 weeks, participants will receive DAOIB and will be closely monitored at various times throughout the study. Researchers will check their blood for specific markers that may indicate how well the treatment is working. They believe that these markers can help predict the effectiveness of DAOIB in improving symptoms of dementia.

To be eligible for this trial, participants must have a clinical diagnosis of Alzheimer's disease or mild cognitive impairment and a specific score on a standard memory test (MMSE) between 10 and 26. They should also have a Clinical Dementia Rating (CDR) score of 1 or 0.5, which indicates mild impairment. However, individuals with certain conditions, like severe depression, substance abuse issues, or other major illnesses, will not be included. If you or a loved one meet the eligibility criteria, this study may offer an opportunity to explore a new treatment option while contributing to important research on dementia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
• • MMSE between 10-26
• • CDR 1 or 0.5
• Exclusion Criteria:
• • Hachinski Ischemic Score \> 4
• • Substance abuse/dependence
• • Parkinson disease, epilepsy, dementia with psychotic features
• • Major depressive disorder
• • Major physical illnesses
• • Severe visual or hearing impairment